Effective treatment of a refractory case of systemic lupus erythematosus with low-dose tacrolimus

Japanese Journal of Nephrology

Volumn 49, Issue 8, 2007, Pages 1020-1024

  Oki, Eishin ^a   Tsugawa, Koji ^a   Suzuki, Koichi ^a   Tanaka, Hiroshi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Systemic lupus erythematosus; Systemic lupus erythematosus disease activity index; Tacrolimus

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FERRITIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; SYSTEMIC LUPUS ERYTHEMATOSUS; WORLD HEALTH ORGANIZATION; DRUG ADMINISTRATION; DRUG COMBINATION; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREDNISOLONE; RECURRENCE; TACROLIMUS; TREATMENT OUTCOME;

EID: 56549118216     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992 ; 35 : 630-640.
2. Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. Rheumatology (Oxford) 2006 ; 45 : 441-444.
3. Politt D, Heinz B, Floege J, Mertens PR. Tacrolimus (FK506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 2004 ; 62 : 49-53.
4. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997 ; 56 : 609-692.
5. Kondo H, Abe T, Hashimoto H, Uchida S. Irimajiri S, Hara M, Sugawara S. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis : A randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004 ; 31 : 243-251.
6. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis : An open-labeled pilot study. Kidney Int 2005 ; 68 : 813-817.
7. Tanaka H, Tsugawa K, Suzuki K, Oki E, Nonaka K, Kimura S, Ito E. Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr 2007 ; 166 : 1053-1055.
8. Maruyama M, Yamasaki Y, Sada K, Sarai A, Ujike K, Maeshima Y, Nakamura Y, Sugiyama H, Makino H. Good response of membranous lupus nephritis to tacrolimus : case report. Clin Nephrol 2006 ; 65 : 276-279.
9. Japanese source
10. Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand. Biochemistry 2005 ; 44 : 2030-2038.